| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 106 | 2022 | 1007 | 17.520 |
Why?
|
| Lung Neoplasms | 146 | 2022 | 2125 | 15.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 103 | 2022 | 986 | 15.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 126 | 2022 | 2318 | 15.220 |
Why?
|
| Carcinoma, Squamous Cell | 75 | 2021 | 1036 | 9.910 |
Why?
|
| Chemoradiotherapy | 32 | 2022 | 290 | 5.980 |
Why?
|
| Antineoplastic Agents | 75 | 2022 | 2364 | 5.900 |
Why?
|
| Neoplasm Recurrence, Local | 50 | 2022 | 1189 | 5.020 |
Why?
|
| Papillomavirus Infections | 12 | 2022 | 196 | 4.410 |
Why?
|
| Small Cell Lung Carcinoma | 20 | 2021 | 85 | 4.020 |
Why?
|
| Carboplatin | 40 | 2022 | 272 | 3.790 |
Why?
|
| Combined Modality Therapy | 63 | 2021 | 1683 | 3.530 |
Why?
|
| Oropharyngeal Neoplasms | 8 | 2022 | 118 | 3.460 |
Why?
|
| Quinazolines | 22 | 2015 | 220 | 3.390 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2020 | 566 | 3.380 |
Why?
|
| Paclitaxel | 40 | 2022 | 464 | 3.200 |
Why?
|
| Aged | 187 | 2021 | 18556 | 3.160 |
Why?
|
| Neoplasm Staging | 74 | 2022 | 1930 | 2.940 |
Why?
|
| Disease-Free Survival | 57 | 2020 | 1198 | 2.830 |
Why?
|
| Middle Aged | 189 | 2022 | 25658 | 2.760 |
Why?
|
| Humans | 325 | 2022 | 83704 | 2.740 |
Why?
|
| Aged, 80 and over | 100 | 2021 | 6594 | 2.490 |
Why?
|
| Male | 206 | 2022 | 42001 | 2.420 |
Why?
|
| Survival Rate | 54 | 2021 | 1923 | 2.390 |
Why?
|
| Female | 208 | 2022 | 44883 | 2.320 |
Why?
|
| Adult | 153 | 2022 | 26064 | 2.250 |
Why?
|
| Clinical Trials as Topic | 24 | 2021 | 1201 | 2.230 |
Why?
|
| Papillomaviridae | 9 | 2022 | 141 | 2.220 |
Why?
|
| Treatment Outcome | 88 | 2022 | 7922 | 2.120 |
Why?
|
| Cisplatin | 31 | 2022 | 582 | 2.110 |
Why?
|
| Adenocarcinoma | 24 | 2016 | 1196 | 2.050 |
Why?
|
| Induction Chemotherapy | 12 | 2022 | 138 | 2.040 |
Why?
|
| Carcinoma, Small Cell | 11 | 2017 | 140 | 1.940 |
Why?
|
| Taxoids | 17 | 2017 | 131 | 1.920 |
Why?
|
| Survival Analysis | 45 | 2020 | 1589 | 1.920 |
Why?
|
| Indoles | 15 | 2017 | 335 | 1.870 |
Why?
|
| Camptothecin | 14 | 2013 | 195 | 1.820 |
Why?
|
| Radiotherapy Dosage | 30 | 2021 | 480 | 1.720 |
Why?
|
| Antibodies, Monoclonal | 20 | 2021 | 1524 | 1.690 |
Why?
|
| Radiotherapy | 15 | 2011 | 339 | 1.650 |
Why?
|
| Pyrroles | 7 | 2017 | 220 | 1.620 |
Why?
|
| Fluorouracil | 25 | 2014 | 563 | 1.610 |
Why?
|
| Radiation-Sensitizing Agents | 6 | 2013 | 102 | 1.580 |
Why?
|
| Mesothelioma | 13 | 2017 | 296 | 1.490 |
Why?
|
| Hydroxyurea | 20 | 2014 | 230 | 1.460 |
Why?
|
| Laryngeal Neoplasms | 5 | 2013 | 86 | 1.420 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2015 | 468 | 1.410 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2021 | 579 | 1.390 |
Why?
|
| Deoxycytidine | 14 | 2012 | 241 | 1.380 |
Why?
|
| Mouth Neoplasms | 9 | 2018 | 181 | 1.370 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2016 | 292 | 1.340 |
Why?
|
| Benzimidazoles | 4 | 2021 | 137 | 1.320 |
Why?
|
| Prognosis | 47 | 2022 | 3716 | 1.310 |
Why?
|
| Etoposide | 15 | 2021 | 198 | 1.310 |
Why?
|
| Proto-Oncogene Proteins c-met | 16 | 2021 | 202 | 1.310 |
Why?
|
| Sirolimus | 3 | 2020 | 171 | 1.270 |
Why?
|
| Medical Oncology | 7 | 2021 | 332 | 1.200 |
Why?
|
| Salvage Therapy | 9 | 2014 | 224 | 1.090 |
Why?
|
| Guanine | 8 | 2014 | 208 | 1.040 |
Why?
|
| Maximum Tolerated Dose | 13 | 2018 | 270 | 1.010 |
Why?
|
| Esophageal Neoplasms | 5 | 2012 | 347 | 1.010 |
Why?
|
| Quality of Life | 16 | 2017 | 1373 | 0.990 |
Why?
|
| Clinical Trials, Phase II as Topic | 8 | 2017 | 171 | 0.970 |
Why?
|
| Deglutition | 9 | 2020 | 68 | 0.970 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2021 | 163 | 0.970 |
Why?
|
| Antibodies, Monoclonal, Humanized | 18 | 2018 | 942 | 0.970 |
Why?
|
| Liver Neoplasms | 8 | 2018 | 636 | 0.960 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2013 | 383 | 0.960 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2021 | 862 | 0.950 |
Why?
|
| Neoplasms, Second Primary | 8 | 2011 | 251 | 0.950 |
Why?
|
| Pancreatic Neoplasms | 4 | 2010 | 674 | 0.930 |
Why?
|
| Radiotherapy, Conformal | 5 | 2011 | 87 | 0.920 |
Why?
|
| Immunotherapy | 6 | 2021 | 583 | 0.910 |
Why?
|
| Drug Monitoring | 2 | 2022 | 121 | 0.900 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2017 | 899 | 0.890 |
Why?
|
| Disease Progression | 22 | 2021 | 1474 | 0.870 |
Why?
|
| DNA, Viral | 1 | 2022 | 282 | 0.870 |
Why?
|
| Pleural Neoplasms | 5 | 2020 | 183 | 0.870 |
Why?
|
| Neoplasm Metastasis | 19 | 2020 | 1052 | 0.870 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 273 | 0.860 |
Why?
|
| Cyclooxygenase 2 | 4 | 2017 | 97 | 0.840 |
Why?
|
| Carcinoma | 8 | 2022 | 441 | 0.840 |
Why?
|
| Carcinoma, Large Cell | 7 | 2014 | 41 | 0.830 |
Why?
|
| Thoracic Neoplasms | 4 | 2018 | 60 | 0.780 |
Why?
|
| Enzyme Inhibitors | 7 | 2014 | 674 | 0.780 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 153 | 0.750 |
Why?
|
| Glutamates | 6 | 2014 | 93 | 0.730 |
Why?
|
| Neoplasms | 16 | 2021 | 2709 | 0.720 |
Why?
|
| Terminal Care | 1 | 2019 | 139 | 0.710 |
Why?
|
| Vinblastine | 3 | 2002 | 109 | 0.710 |
Why?
|
| Drug Administration Schedule | 17 | 2020 | 973 | 0.690 |
Why?
|
| Organoplatinum Compounds | 4 | 2006 | 99 | 0.690 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2015 | 308 | 0.690 |
Why?
|
| Stomach Neoplasms | 3 | 2011 | 263 | 0.660 |
Why?
|
| Follow-Up Studies | 24 | 2021 | 3881 | 0.650 |
Why?
|
| Time Factors | 21 | 2021 | 5506 | 0.650 |
Why?
|
| Peritoneal Neoplasms | 4 | 2012 | 179 | 0.650 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 36 | 0.650 |
Why?
|
| Quality of Health Care | 2 | 2019 | 366 | 0.650 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 384 | 0.640 |
Why?
|
| Colorectal Neoplasms | 5 | 2011 | 859 | 0.640 |
Why?
|
| Thionucleotides | 2 | 2008 | 59 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 7 | 2022 | 272 | 0.630 |
Why?
|
| Organ Sparing Treatments | 2 | 2013 | 35 | 0.620 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 20 | 0.610 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2015 | 19 | 0.610 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2015 | 161 | 0.600 |
Why?
|
| Speech | 2 | 2013 | 72 | 0.590 |
Why?
|
| Exanthema | 3 | 2014 | 32 | 0.580 |
Why?
|
| Remission Induction | 10 | 2014 | 716 | 0.570 |
Why?
|
| Patient Selection | 8 | 2021 | 700 | 0.570 |
Why?
|
| Platinum Compounds | 3 | 2022 | 31 | 0.550 |
Why?
|
| Pyridines | 5 | 2019 | 309 | 0.530 |
Why?
|
| Neck Dissection | 6 | 2010 | 72 | 0.520 |
Why?
|
| Blood Proteins | 1 | 2014 | 160 | 0.520 |
Why?
|
| Neutropenia | 6 | 2017 | 223 | 0.490 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 532 | 0.490 |
Why?
|
| DNA Repair | 2 | 2014 | 351 | 0.490 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 171 | 0.480 |
Why?
|
| Platinum | 7 | 2022 | 58 | 0.480 |
Why?
|
| Cell Line, Tumor | 20 | 2021 | 2434 | 0.480 |
Why?
|
| Mutation | 16 | 2017 | 3872 | 0.470 |
Why?
|
| Proteomics | 1 | 2014 | 191 | 0.470 |
Why?
|
| Publishing | 1 | 2013 | 90 | 0.470 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2017 | 308 | 0.470 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 339 | 0.470 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2013 | 250 | 0.460 |
Why?
|
| Sulfonamides | 9 | 2014 | 329 | 0.460 |
Why?
|
| DNA-Binding Proteins | 3 | 2015 | 1212 | 0.460 |
Why?
|
| Radiosurgery | 3 | 2021 | 256 | 0.450 |
Why?
|
| Retrospective Studies | 25 | 2021 | 7701 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 3 | 2017 | 36 | 0.450 |
Why?
|
| Lung | 3 | 2013 | 1067 | 0.440 |
Why?
|
| Receptors, Growth Factor | 5 | 2011 | 56 | 0.430 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2016 | 44 | 0.430 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 38 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2017 | 1210 | 0.430 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 872 | 0.430 |
Why?
|
| Area Under Curve | 6 | 2018 | 345 | 0.420 |
Why?
|
| Signal Transduction | 11 | 2019 | 3309 | 0.420 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2012 | 298 | 0.420 |
Why?
|
| Maintenance Chemotherapy | 3 | 2020 | 77 | 0.400 |
Why?
|
| Methotrexate | 2 | 2017 | 263 | 0.400 |
Why?
|
| Receptor, EphB4 | 3 | 2015 | 27 | 0.400 |
Why?
|
| Age Factors | 7 | 2018 | 1919 | 0.390 |
Why?
|
| Carmustine | 2 | 2006 | 72 | 0.390 |
Why?
|
| Immunoconjugates | 2 | 2021 | 114 | 0.380 |
Why?
|
| Piperazines | 8 | 2019 | 270 | 0.380 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2006 | 118 | 0.380 |
Why?
|
| Administration, Oral | 9 | 2020 | 727 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2018 | 2100 | 0.380 |
Why?
|
| Arsenicals | 1 | 2008 | 42 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2021 | 2715 | 0.370 |
Why?
|
| Oxides | 1 | 2008 | 49 | 0.370 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2017 | 678 | 0.370 |
Why?
|
| Fatigue | 3 | 2018 | 169 | 0.360 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2011 | 60 | 0.360 |
Why?
|
| Prostatic Neoplasms | 5 | 2011 | 1486 | 0.360 |
Why?
|
| Smoking | 6 | 2014 | 569 | 0.360 |
Why?
|
| Infusions, Intravenous | 8 | 2018 | 448 | 0.360 |
Why?
|
| Double-Blind Method | 5 | 2017 | 1906 | 0.350 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 1824 | 0.350 |
Why?
|
| Indazoles | 4 | 2013 | 71 | 0.350 |
Why?
|
| International Cooperation | 3 | 2018 | 135 | 0.350 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 82 | 0.340 |
Why?
|
| Consolidation Chemotherapy | 2 | 2018 | 21 | 0.340 |
Why?
|
| Suramin | 2 | 2004 | 27 | 0.330 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2003 | 15 | 0.330 |
Why?
|
| Prospective Studies | 12 | 2022 | 4099 | 0.330 |
Why?
|
| Lymph Nodes | 5 | 2019 | 535 | 0.330 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 25 | 0.320 |
Why?
|
| Pyrimidines | 4 | 2012 | 402 | 0.320 |
Why?
|
| Niacinamide | 5 | 2013 | 117 | 0.320 |
Why?
|
| DNA | 1 | 2012 | 1306 | 0.320 |
Why?
|
| Young Adult | 10 | 2022 | 5983 | 0.320 |
Why?
|
| Thiazoles | 3 | 2012 | 130 | 0.320 |
Why?
|
| Anemia | 4 | 2017 | 127 | 0.310 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 1012 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 102 | 0.310 |
Why?
|
| Risk Factors | 12 | 2018 | 5433 | 0.310 |
Why?
|
| Benzenesulfonates | 3 | 2010 | 64 | 0.310 |
Why?
|
| Gene Rearrangement | 2 | 2017 | 169 | 0.310 |
Why?
|
| Tubulin Modulators | 2 | 2021 | 28 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 417 | 0.310 |
Why?
|
| Gallbladder Neoplasms | 1 | 2005 | 28 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1087 | 0.300 |
Why?
|
| Mouth | 2 | 2018 | 54 | 0.300 |
Why?
|
| Dacarbazine | 1 | 2006 | 113 | 0.300 |
Why?
|
| Research Design | 4 | 2015 | 569 | 0.300 |
Why?
|
| Placebos | 5 | 2015 | 233 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 200 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 356 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 70 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 146 | 0.290 |
Why?
|
| Confidence Intervals | 5 | 2018 | 233 | 0.280 |
Why?
|
| Boronic Acids | 3 | 2011 | 55 | 0.280 |
Why?
|
| Oligopeptides | 1 | 2005 | 186 | 0.280 |
Why?
|
| Imidazoles | 4 | 2013 | 168 | 0.280 |
Why?
|
| Radiation Dosage | 3 | 2020 | 227 | 0.270 |
Why?
|
| Pneumonectomy | 3 | 2018 | 186 | 0.270 |
Why?
|
| Pyrazines | 3 | 2011 | 86 | 0.270 |
Why?
|
| Mouthwashes | 1 | 2003 | 5 | 0.270 |
Why?
|
| Cyclosporine | 1 | 2005 | 253 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2017 | 464 | 0.270 |
Why?
|
| Sarcoma | 1 | 2006 | 215 | 0.270 |
Why?
|
| Feasibility Studies | 4 | 2022 | 759 | 0.270 |
Why?
|
| United States | 12 | 2022 | 6355 | 0.270 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 273 | 0.270 |
Why?
|
| Radiography | 4 | 2014 | 876 | 0.270 |
Why?
|
| Viral Vaccines | 1 | 2003 | 41 | 0.260 |
Why?
|
| Tretinoin | 2 | 2021 | 126 | 0.260 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 26 | 0.260 |
Why?
|
| Immunoblotting | 5 | 2017 | 279 | 0.260 |
Why?
|
| Travel | 1 | 2003 | 66 | 0.260 |
Why?
|
| Quinolones | 1 | 2003 | 57 | 0.250 |
Why?
|
| Tongue Neoplasms | 3 | 2018 | 52 | 0.250 |
Why?
|
| Gene Expression | 5 | 2017 | 1333 | 0.240 |
Why?
|
| Phosphorylation | 7 | 2017 | 1159 | 0.240 |
Why?
|
| Drug Eruptions | 2 | 2017 | 38 | 0.240 |
Why?
|
| Attitude to Health | 1 | 2004 | 224 | 0.240 |
Why?
|
| Cranial Irradiation | 3 | 2018 | 36 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 181 | 0.240 |
Why?
|
| Brain Neoplasms | 3 | 2012 | 807 | 0.240 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 206 | 0.230 |
Why?
|
| Chicago | 4 | 2014 | 1454 | 0.230 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 171 | 0.230 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2010 | 62 | 0.230 |
Why?
|
| Melanoma | 2 | 2005 | 515 | 0.220 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 32 | 0.220 |
Why?
|
| Focal Adhesions | 2 | 2013 | 69 | 0.220 |
Why?
|
| Research Report | 1 | 2021 | 43 | 0.220 |
Why?
|
| Genomics | 3 | 2016 | 648 | 0.220 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 821 | 0.220 |
Why?
|
| Paxillin | 2 | 2013 | 61 | 0.210 |
Why?
|
| Pyrrolidinones | 1 | 2020 | 17 | 0.210 |
Why?
|
| RNA, Small Interfering | 8 | 2017 | 568 | 0.210 |
Why?
|
| Sex Factors | 4 | 2019 | 1090 | 0.210 |
Why?
|
| Topoisomerase I Inhibitors | 5 | 2013 | 36 | 0.200 |
Why?
|
| Aminopyridines | 1 | 2019 | 30 | 0.200 |
Why?
|
| Morpholines | 1 | 2019 | 80 | 0.200 |
Why?
|
| Mucositis | 2 | 2017 | 22 | 0.200 |
Why?
|
| Quinolines | 1 | 2020 | 98 | 0.200 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 1027 | 0.190 |
Why?
|
| Survival | 3 | 2003 | 23 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1766 | 0.190 |
Why?
|
| Pharynx | 1 | 2018 | 38 | 0.190 |
Why?
|
| Epothilones | 2 | 2009 | 13 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2011 | 167 | 0.190 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2014 | 83 | 0.190 |
Why?
|
| Phenylurea Compounds | 4 | 2013 | 110 | 0.190 |
Why?
|
| Erythropoietin | 3 | 2013 | 92 | 0.190 |
Why?
|
| Adolescent | 6 | 2022 | 9178 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2009 | 80 | 0.180 |
Why?
|
| Radiation Injuries | 2 | 2018 | 161 | 0.180 |
Why?
|
| Health Resources | 1 | 2019 | 79 | 0.180 |
Why?
|
| Depsipeptides | 2 | 2010 | 30 | 0.180 |
Why?
|
| Gene Dosage | 7 | 2013 | 216 | 0.180 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 8 | 0.180 |
Why?
|
| Dental Alloys | 1 | 2018 | 7 | 0.180 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 16 | 0.180 |
Why?
|
| Hemoptysis | 1 | 2018 | 24 | 0.180 |
Why?
|
| DNA Topoisomerases, Type I | 3 | 2013 | 28 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 325 | 0.180 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 190 | 0.180 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 542 | 0.180 |
Why?
|
| Macrophages | 1 | 2021 | 562 | 0.180 |
Why?
|
| Mice | 11 | 2021 | 11173 | 0.170 |
Why?
|
| Vision Disorders | 1 | 2018 | 69 | 0.170 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2009 | 52 | 0.170 |
Why?
|
| Retreatment | 3 | 2012 | 106 | 0.170 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1373 | 0.170 |
Why?
|
| Genotype | 5 | 2015 | 1856 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2007 | 402 | 0.170 |
Why?
|
| Mice, Nude | 4 | 2012 | 786 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2008 | 683 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 2572 | 0.170 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 69 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 158 | 0.170 |
Why?
|
| Animals | 14 | 2021 | 27044 | 0.170 |
Why?
|
| Pyrazoles | 3 | 2011 | 168 | 0.170 |
Why?
|
| Life Style | 1 | 2018 | 191 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2012 | 359 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 220 | 0.160 |
Why?
|
| Paired Box Transcription Factors | 2 | 2014 | 51 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2007 | 23 | 0.160 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 326 | 0.160 |
Why?
|
| Probability | 3 | 2008 | 360 | 0.160 |
Why?
|
| Lymphatic Metastasis | 4 | 2014 | 508 | 0.160 |
Why?
|
| SEER Program | 1 | 2016 | 193 | 0.150 |
Why?
|
| Kidney Neoplasms | 3 | 2007 | 595 | 0.150 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 1064 | 0.150 |
Why?
|
| Cell Movement | 6 | 2017 | 745 | 0.150 |
Why?
|
| Fractals | 1 | 2015 | 45 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2015 | 60 | 0.150 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 25 | 0.150 |
Why?
|
| Bryostatins | 2 | 2006 | 15 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2011 | 68 | 0.140 |
Why?
|
| Cell Proliferation | 8 | 2015 | 1619 | 0.140 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 269 | 0.140 |
Why?
|
| Health Status | 2 | 2009 | 365 | 0.140 |
Why?
|
| Radiation, Ionizing | 2 | 2012 | 126 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 399 | 0.140 |
Why?
|
| Incidence | 5 | 2018 | 1644 | 0.140 |
Why?
|
| Isotretinoin | 2 | 2006 | 22 | 0.140 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 75 | 0.140 |
Why?
|
| Mass Screening | 2 | 2013 | 626 | 0.140 |
Why?
|
| Treatment Failure | 5 | 2010 | 303 | 0.140 |
Why?
|
| Preoperative Care | 3 | 2009 | 418 | 0.140 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 82 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 584 | 0.130 |
Why?
|
| Cell Survival | 5 | 2017 | 1015 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2017 | 34 | 0.130 |
Why?
|
| Gene Amplification | 2 | 2018 | 134 | 0.130 |
Why?
|
| Population Groups | 1 | 2013 | 42 | 0.130 |
Why?
|
| Farnesyltranstransferase | 2 | 2003 | 6 | 0.130 |
Why?
|
| Forecasting | 2 | 2021 | 323 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2016 | 2288 | 0.130 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2013 | 15 | 0.130 |
Why?
|
| Erythropoiesis | 1 | 2013 | 50 | 0.130 |
Why?
|
| Glucuronosyltransferase | 2 | 2006 | 188 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 200 | 0.130 |
Why?
|
| Interferon-alpha | 3 | 2010 | 239 | 0.130 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 275 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2013 | 157 | 0.130 |
Why?
|
| Dehydration | 1 | 2013 | 23 | 0.130 |
Why?
|
| Esophagitis | 1 | 2013 | 42 | 0.130 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 410 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2014 | 346 | 0.130 |
Why?
|
| HeLa Cells | 1 | 2014 | 512 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 306 | 0.120 |
Why?
|
| Osteoradionecrosis | 2 | 2010 | 14 | 0.120 |
Why?
|
| Universities | 2 | 2010 | 134 | 0.120 |
Why?
|
| Keratin-19 | 1 | 2012 | 11 | 0.120 |
Why?
|
| Ketones | 1 | 2012 | 12 | 0.120 |
Why?
|
| Furans | 1 | 2012 | 18 | 0.120 |
Why?
|
| Dexamethasone | 2 | 2004 | 314 | 0.120 |
Why?
|
| Radiation Tolerance | 2 | 2021 | 175 | 0.120 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2011 | 23 | 0.120 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 539 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 48 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2004 | 313 | 0.120 |
Why?
|
| Phthalazines | 1 | 2011 | 30 | 0.120 |
Why?
|
| Ovarian Neoplasms | 2 | 2008 | 686 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2016 | 502 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2007 | 454 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 157 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2013 | 345 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1180 | 0.110 |
Why?
|
| Organ Preservation | 1 | 2011 | 69 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2012 | 62 | 0.110 |
Why?
|
| Genes, ras | 1 | 2011 | 99 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 71 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 168 | 0.110 |
Why?
|
| Rad51 Recombinase | 2 | 2014 | 81 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2010 | 6 | 0.110 |
Why?
|
| Mucins | 1 | 2010 | 44 | 0.110 |
Why?
|
| Community Networks | 2 | 2018 | 35 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2011 | 963 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 123 | 0.100 |
Why?
|
| Developing Countries | 1 | 2010 | 73 | 0.100 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 20 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 122 | 0.100 |
Why?
|
| Health Facilities | 1 | 2009 | 27 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 330 | 0.100 |
Why?
|
| Tissue Array Analysis | 3 | 2017 | 128 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2010 | 312 | 0.100 |
Why?
|
| ras Proteins | 1 | 2010 | 133 | 0.100 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 32 | 0.100 |
Why?
|
| Diarrhea | 3 | 2008 | 208 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 2309 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2266 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 287 | 0.100 |
Why?
|
| Mesna | 1 | 2008 | 10 | 0.100 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 50 | 0.100 |
Why?
|
| Receptor, erbB-2 | 2 | 2011 | 193 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 320 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2017 | 244 | 0.090 |
Why?
|
| Macrolides | 2 | 2012 | 32 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.090 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 107 | 0.090 |
Why?
|
| Patient Care | 1 | 2009 | 88 | 0.090 |
Why?
|
| Eicosanoids | 1 | 2008 | 16 | 0.090 |
Why?
|
| Skin | 1 | 2012 | 560 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 34 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2010 | 278 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2008 | 36 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 265 | 0.090 |
Why?
|
| Pain | 2 | 2017 | 363 | 0.090 |
Why?
|
| Pneumonia, Aspiration | 1 | 2007 | 19 | 0.090 |
Why?
|
| Technology, Radiologic | 1 | 2008 | 102 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 370 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 1210 | 0.090 |
Why?
|
| Azacitidine | 1 | 2008 | 122 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2009 | 269 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2013 | 288 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 123 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2008 | 301 | 0.080 |
Why?
|
| Models, Biological | 2 | 2015 | 1798 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 628 | 0.080 |
Why?
|
| Tongue | 1 | 2007 | 57 | 0.080 |
Why?
|
| Oncogenes | 1 | 2007 | 90 | 0.080 |
Why?
|
| Multienzyme Complexes | 2 | 2004 | 66 | 0.080 |
Why?
|
| Triazines | 1 | 2007 | 48 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2010 | 184 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 2 | 2004 | 91 | 0.080 |
Why?
|
| DNA Primers | 3 | 2014 | 571 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2008 | 165 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2004 | 103 | 0.080 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2006 | 21 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 26 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2007 | 165 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 39 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 119 | 0.080 |
Why?
|
| Activin Receptors, Type I | 1 | 2005 | 12 | 0.080 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 35 | 0.080 |
Why?
|
| Base Sequence | 4 | 2014 | 2431 | 0.080 |
Why?
|
| Observation | 2 | 2020 | 39 | 0.080 |
Why?
|
| Phospholipids | 1 | 2006 | 127 | 0.080 |
Why?
|
| Illinois | 2 | 2007 | 472 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2008 | 259 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 42 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 73 | 0.080 |
Why?
|
| Physician's Role | 1 | 2007 | 187 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2007 | 577 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2019 | 167 | 0.080 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 92 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 304 | 0.070 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 57 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2006 | 287 | 0.070 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2005 | 15 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 82 | 0.070 |
Why?
|
| Algorithms | 3 | 2013 | 1850 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2005 | 271 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2006 | 249 | 0.070 |
Why?
|
| Radiometry | 1 | 2004 | 49 | 0.070 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2008 | 274 | 0.070 |
Why?
|
| Speech Intelligibility | 1 | 2004 | 10 | 0.070 |
Why?
|
| Voice | 1 | 2004 | 12 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2018 | 201 | 0.070 |
Why?
|
| Leukemia | 1 | 2006 | 301 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 69 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 2004 | 58 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2006 | 1828 | 0.070 |
Why?
|
| Taste | 1 | 2004 | 27 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2017 | 87 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 155 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2003 | 98 | 0.070 |
Why?
|
| Logistic Models | 3 | 2018 | 1165 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 83 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 74 | 0.070 |
Why?
|
| Nausea | 1 | 2005 | 169 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 156 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 268 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 439 | 0.070 |
Why?
|
| Vomiting | 1 | 2005 | 186 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 72 | 0.060 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 2175 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2008 | 580 | 0.060 |
Why?
|
| Mastication | 1 | 2004 | 67 | 0.060 |
Why?
|
| Lactones | 1 | 2003 | 33 | 0.060 |
Why?
|
| Premedication | 1 | 2003 | 58 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 326 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 324 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 410 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2003 | 203 | 0.060 |
Why?
|
| Contrast Media | 2 | 2009 | 1084 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2003 | 72 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 703 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 153 | 0.060 |
Why?
|
| Cause of Death | 1 | 2004 | 279 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 2 | 2013 | 71 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2003 | 348 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 992 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2005 | 275 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 320 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 233 | 0.060 |
Why?
|
| RNA Interference | 2 | 2017 | 378 | 0.060 |
Why?
|
| Registries | 1 | 2006 | 667 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 104 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2003 | 237 | 0.060 |
Why?
|
| Receptors, CCR2 | 1 | 2021 | 34 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 836 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 156 | 0.060 |
Why?
|
| DNA Damage | 2 | 2014 | 357 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2003 | 326 | 0.050 |
Why?
|
| Apoptosis | 3 | 2014 | 1782 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2003 | 361 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 767 | 0.050 |
Why?
|
| Comorbidity | 1 | 2004 | 940 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2011 | 148 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1301 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 163 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2021 | 462 | 0.050 |
Why?
|
| Infant | 1 | 2006 | 3118 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 696 | 0.050 |
Why?
|
| Sulindac | 2 | 2009 | 11 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 400 | 0.050 |
Why?
|
| Oral Health | 1 | 2018 | 10 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 190 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 320 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 516 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 170 | 0.040 |
Why?
|
| Social Participation | 1 | 2017 | 13 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 1310 | 0.040 |
Why?
|
| Anorexia | 1 | 2017 | 29 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 91 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 21 | 0.040 |
Why?
|
| African Americans | 1 | 2005 | 1168 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 946 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 530 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2017 | 70 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 520 | 0.040 |
Why?
|
| Proteolysis | 1 | 2017 | 99 | 0.040 |
Why?
|
| Weight Loss | 1 | 2019 | 234 | 0.040 |
Why?
|
| Dyspnea | 1 | 2017 | 80 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 763 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2017 | 149 | 0.040 |
Why?
|
| Decision Making | 1 | 2002 | 619 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 1000 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1962 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 374 | 0.040 |
Why?
|
| Cell Line | 2 | 2011 | 2617 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 76 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2015 | 51 | 0.040 |
Why?
|
| Thalidomide | 1 | 2015 | 54 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 2784 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 15 | 0.040 |
Why?
|
| Safety | 2 | 2008 | 174 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 50 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 366 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 23 | 0.030 |
Why?
|
| Biopsy | 2 | 2009 | 1182 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 147 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 109 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 178 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 187 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2013 | 76 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 204 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 483 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 335 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 7 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 115 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2012 | 19 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 297 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2011 | 22 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 55 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 737 | 0.030 |
Why?
|
| Alleles | 2 | 2006 | 1117 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 209 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 331 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3276 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 17 | 0.030 |
Why?
|
| California | 1 | 2011 | 135 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 34 | 0.030 |
Why?
|
| Computational Biology | 1 | 2015 | 530 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2011 | 31 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 286 | 0.030 |
Why?
|
| Thorax | 1 | 2011 | 52 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2011 | 76 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2011 | 46 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 132 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 54 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 283 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 646 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2010 | 81 | 0.030 |
Why?
|
| Endonucleases | 1 | 2010 | 21 | 0.030 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2010 | 32 | 0.030 |
Why?
|
| Leucovorin | 1 | 2010 | 219 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 64 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 61 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 119 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2009 | 19 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 68 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 77 | 0.030 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2009 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 108 | 0.030 |
Why?
|
| Peptides | 1 | 2013 | 642 | 0.030 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 48 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3194 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 143 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 130 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 125 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 350 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 282 | 0.020 |
Why?
|
| Pneumonia | 1 | 2010 | 156 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 369 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 28 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 10 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2008 | 30 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 162 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 417 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
| Community Health Services | 1 | 2009 | 70 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 232 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 42 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 521 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 832 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 78 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 728 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 217 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 461 | 0.020 |
Why?
|
| Topotecan | 1 | 2007 | 46 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 331 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 142 | 0.020 |
Why?
|
| Health Transition | 1 | 2007 | 2 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2008 | 165 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 1204 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 125 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 1088 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 394 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 224 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 590 | 0.020 |
Why?
|
| Video Recording | 1 | 2007 | 191 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 668 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 2005 | 17 | 0.020 |
Why?
|
| Stem Cells | 1 | 2008 | 354 | 0.020 |
Why?
|
| Mandibular Diseases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 784 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 396 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 714 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 47 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2005 | 214 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 81 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 107 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2005 | 89 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2004 | 13 | 0.020 |
Why?
|
| Antidiarrheals | 1 | 2004 | 14 | 0.020 |
Why?
|
| Research | 1 | 2005 | 258 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2008 | 355 | 0.020 |
Why?
|
| Benzamides | 1 | 2005 | 219 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 549 | 0.020 |
Why?
|
| Bilirubin | 1 | 2004 | 129 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 286 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1531 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 264 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2005 | 295 | 0.020 |
Why?
|
| Biological Availability | 1 | 2002 | 105 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 700 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 755 | 0.010 |
Why?
|
| Child | 1 | 2012 | 6794 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1781 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 453 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 1607 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 562 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 2302 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1252 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 816 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1361 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 2230 | 0.010 |
Why?
|